Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ITCA 650 in Type 2 Diabetes
NCT00943917Phase 2Completed
- Sponsor
- Intarcia Therapeutics
- Start
- Aug 2009
- Primary completion
- Aug 2010
- Modality
- Peptides, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ITCA 650 in type 2 diabetes mellitus (T2DM) (9 arms), sponsored by Intarcia Therapeutics. Primary endpoint: Mean Change in HbA1c at 48 weeks. Started Aug 2009; status: completed.
02
Drugs
ITCA 650
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00943917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943917.